Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland.

Vallejo-Yagüe, Enriqueta; Burkard, Theresa; Möller, Burkhard; Finckh, Axel; Burden, Andrea M (2021). Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland. Journal of clinical medicine, 10(14) MDPI 10.3390/jcm10143194

[img]
Preview
Text
jcm-10-03194.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Abnormal body mass index (BMI) was associated with worse rheumatic markers in psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Aiming to describe PsA and RA patients stratified by BMI, we performed a descriptive study in PsA and RA patients (two distinct cohorts) in the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry. New users of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) were stratified by BMI at the start of their treatment (underweight, normal weight, overweight, obese). The PsA underweight and normal weight categories were merged. Age at disease onset and further characteristics at the start of the first b/tsDMARD treatment were compared across BMI categories vs. the corresponding normal weight group. The study included 819 PsA (36.5% overweight, 23.8% obese) and 3217 RA patients (4.4% underweight, 31.8% overweight, 17.0% obese). Compared to the corresponding normal weight group, PsA and RA obese patients had significantly (p < 0.05) higher C-reactive protein, worse disease activity, and lower quality of life (QoL). Obese PsA patients had significantly worse skin manifestation and pain, while obese RA patients had significantly higher erythrocyte sedimentation rate and tender joint counts, as well as lower seropositive prevalence. To conclude, obese PsA and RA patients presented worse disease activity and poorer QoL than those with normal weight.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Möller, Burkhard

Subjects:

600 Technology > 610 Medicine & health
600 Technology > 610 Medicine & health > 615 Pharmacology & therapeutics, prescription drugs

ISSN:

2077-0383

Publisher:

MDPI

Language:

English

Submitter:

Burkhard Möller

Date Deposited:

03 Dec 2021 17:54

Last Modified:

05 Dec 2022 15:54

Publisher DOI:

10.3390/jcm10143194

PubMed ID:

34300360

Uncontrolled Keywords:

biologics patient-reported outcomes psoriatic arthritis rheumatoid arthritis

BORIS DOI:

10.48350/161242

URI:

https://boris.unibe.ch/id/eprint/161242

Actions (login required)

Edit item Edit item
Provide Feedback